

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 8, 2009**

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-50761
(Commission File
Number)

11-3146460
(IRS Employer
Identification No.)

603 Queensbury Avenue, Queensbury, New York 12804
(Address of Principal Executive Offices) (Zip Code)

(518) 798-1215
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

Effective May 8, 2009, Eamonn P. Hobbs resigned as a member of the board of directors of AngioDynamics, Inc. (“AngioDynamics”). Mr. Hobbs’ resignation was not the result of any disagreement with AngioDynamics.

On May 11, 2009, AngioDynamics’ Board of Directors appointed Jan Keltjens, President and CEO, to the board to fill the vacancy created by Mr. Hobbs’ resignation. Mr. Keltjens was appointed to the class of directors whose term expires at AngioDynamics’ 2009 annual meeting. The material terms of Mr. Keltjens’ employment arrangement with AngioDynamics were disclosed in AngioDynamics’ Current Report on Form 8-K, filed with the Securities Exchange Commission on January 23, 2009 (the “January 23, 2009 8-K”).

In addition, on May 11, 2009, AngioDynamics’ board of directors agreed to pay Mr. Hobbs an advance of \$200,000 against the amount owed to Mr. Hobbs pursuant to Section 7 of the employment agreement, dated January 20, 2009, between AngioDynamics and Mr. Hobbs. The material terms of the employment agreement were disclosed in, and a copy of the employment agreement was filed as Exhibit 10.5 to, the January 23, 2009 8-K.

Item 7.01 – Regulation FD Disclosure.

On May 11, 2009, AngioDynamics issued a press release announcing the appointment of Mr. Keltjens to AngioDynamics’ board of directors. A copy of the Press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.

The information set forth in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 – Financial Statements and Exhibits.

(d) *Exhibits.*

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated May 11, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.
(Registrant)

Date: May 11, 2009

By: /s/ D. Joseph Gersuk
D. Joseph Gersuk
Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated May 11, 2009.



FOR IMMEDIATE RELEASE

Company Contact:

AngioDynamics, Inc.
D. Joseph Gersuk, CFO
(800) 772-6446 x1608
jgersuk@AngioDynamics.com

Investor Relations Contacts:

EVC Group, Inc.
Doug Sherk/Jenifer Kirtland
(415) 896-2005
dsherk@evcgroup.com
jkirtland@evcgroup.com

Media Contact:

EVC Group, Inc.
Chris Gale/ Steve DiMattia
(646) 201-5431
cgale@evcgroup.com
sdimattia@evcgroup.com

Jan Keltjens Appointed to Board of Directors of AngioDynamics

QUEENSBURY, N.Y. May 11, 2009 — AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced Jan Keltjens, 52, President and Chief Executive Officer of the Company, has been appointed to its Board of Directors. Mr. Keltjens replaces Eamonn Hobbs, who has resigned from the Board of Directors.

“On behalf of the Board of Directors, I would like to thank Eamonn for all his contributions to AngioDynamics, both as the company’s co-founder and previous chief executive officer, as well as most recently as a member of the Board. We all wish him the very best in his future endeavors,” said Vincent Bucci, Chairman of the Board of Directors. “At the same time, the Board looks forward to working with Jan in his expanded role with AngioDynamics. During his short tenure as our president and chief executive officer, his performance has reinforced the Board’s confidence in his leadership of the Company.”

Mr. Keltjens joined AngioDynamics as President and CEO on March 1, 2009. Most recently, he was President and CEO of CryoCath Technologies, Inc. Mr. Keltjens also previously served in various leadership positions at Cordis, a Johnson & Johnson company, including his last position as Worldwide General Manager of Cordis Neurovascular.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company’s diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

#